Herbst… said the pill was proven to be “practice-changing” and should become the “standard of care” for the quarter of lung cancer patients worldwide with the EGFR mutation.

After five years, 88% of patients who took the daily pill after the removal of their tumour were still alive, compared with 78% of patients treated with a placebo. Overall, there was a 51% lower risk of death for those who received osimertinib compared with those who received placebo.

I love seeing cancer genomics research bearing fruit like this. We will hopefully see more and more treatments like this developed for other types/subtypes of cancers.